Cancer in the cervix, which is the lower part of the uterus, is called cervical cancer. Its two primary types are squamous cells cancer and adenocarcinoma. 80% to 90%, i.e., a majority of cervical cancer cases fall under the former category. The latter is less common, constituting 10% to 20% of cases; however, the incidence of adenocarcinoma is rising predominantly in younger girls. Cervical cancer is a common type of cancer occurring in women worldwide. A major cause is infection by human papillomavirus (HPV) which is found in 99% of cervical cancer cases. HPV is sexually transmitted. Around 70% of cervical cancer cases could be attributed to infection caused by two major strains of virus, HPV-16 and HPV-18, which are also termed as high risk HPV types.
Cervical cancer can be prevented via widespread immunization with the HPV vaccine, which prevents infection from high-risk HPV strains and also offers protection against the low-risk ones which cause genital warts. The Center for Disease Control and Prevention (CDC) has recommended that the HPV vaccine be administered to girls and boys falling in the age group of 11 to 12 years old. Vaccination at an early stage of life, during teenage, is highly effective. In October 2016, the CDC updated the schedule of the HPV vaccination. It recommends that all teens and adolescents falling between the ages of 9 and 14 should receive two doses of HPV vaccination within a gap of six months.
The rising rate of cervical cancer among women is of particular concern as it is a significantly common type of cancer and a leading cause of death. Its increasing prevalence worldwide is a major driver for the cervical cancer vaccine market. The global surge in the number of cervical cancer patients, especially in developing countries, has motivated key players to develop new vaccines at a low cost. Most vaccines for cervical cancer are in their late stage of clinical development. The rising incidence of cervical cancer has provoked governments and non-profit organizations to take the initiative to create awareness regarding control & prevention of cervical cancer and HPV vaccinations. However, the high cost of the vaccine and the lack of awareness about HPV vaccination in developing countries are major restraining factors for the cervical cancer vaccine market.
The market can be segmented by vaccine type into the bivalent, quadrivalent, and 9-valent varieties. Currently, Gardasil, Gardasil 9, and Cervarix are the only three vaccines approved by the U.S. FDA and commercially available in market. Gardasil and Gardasil 9 are manufactured by Merck & Co., Inc. and Cervarix by GlaxoSmithKline plc. Gardasil is a quadrivalent vaccine which targets four different strains of HPV: HPV-6, HPV-11, HPV-16, and HPV-18.Cervarix is a bivalent vaccine targeting only two high-risk strains of HPV: HPV-16 and HPV-18.
Geographically, the global cervical cancer vaccine market is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to hold a significant share in the market due to the rising prevalence of cervical cancer and awareness campaigns regarding HPV vaccination by the government and NGOs in the region. Alliances between the public and private sectors for the development of low-cost vaccines, favorable reimbursement policies, and high per capital income levels are also estimated to propel the market in North America. The high incidence of cervical cancer in developing countries and initiatives taken by WHO to develop affordable vaccines for prevention of cervical cancer in low- and middle-income countries are anticipated to drive the market in Asia Pacific, Latin America, and Africa.
Major players operating in the cervical cancer vaccine market include Merck & Co., Inc. and GlaxoSmithKline plc. Another prominent emerging player is ISA Pharmaceuticals B.V., whose immunotherapeutic vaccine is in its phase II trial of clinical development.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.